Status:
COMPLETED
A Multi-Center, Evaluation of the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle
Lead Sponsor:
Aciex Therapeutics, Inc.
Conditions:
Allergic Conjunctivitis
Eligibility:
All Genders
10+ years
Phase:
PHASE3
Brief Summary
The purpose of this study is to evaluate the onset and duration of action of AC-170 0.24% compared to vehicle in the prevention of the signs and symptoms of allergic conjunctivitis in the conjunctival...
Eligibility Criteria
Inclusion
- positive bilateral conjunctival allergen challenge (CAC) reaction
Exclusion
- known contraindications or sensitivities to the study medication or its components
- any ocular condition that, in the opinion of the investigator, could affect the subjects safety trial parameters
- use of disallowed medication during the period indicated prior to the enrollment or during the study
Key Trial Info
Start Date :
June 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2013
Estimated Enrollment :
101 Patients enrolled
Trial Details
Trial ID
NCT01881113
Start Date
June 1 2013
End Date
October 1 2013
Last Update
November 9 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ora, Inc.
Andover, Massachusetts, United States, 01810